Ultragenyx Pharmaceutical Inc. (RARE): Emil D Kakkis , President & CEO of Ultragenyx Pharmaceutical Inc. sold 20,000 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $60.74 per share for a total value of $1,199,094.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 21, 2016, Sunil Agarwal (Chief Medical Officer) sold 649 shares at $70.53 per share price.On Apr 19, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $70.29 per share price.Also, On Dec 18, 2015, Theodore Alan Huizenga (Controller and PAO) sold 1,500 shares at $110.55 per share price.On Dec 14, 2015, Shalini Sharp (CFO & Senior Vice President) sold 12,000 shares at $101.60 per share price.
Shares of Ultragenyx Pharmaceutical Inc (RARE) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -1.72 points or -2.72% at $61.46 with 5,60,195 shares getting traded. Post opening the session at $62.87, the shares hit an intraday low of $60.2901 and an intraday high of $64.59 and the price vacillated in this range throughout the day. The company has a market cap of $2,398 M and the number of outstanding shares has been calculated to be 3,90,20,576 shares. The 52-week high of Ultragenyx Pharmaceutical Inc is $137.05 and the 52-week low is $49.
Company has been under the radar of several Street Analysts.Ultragenyx Pharmaceutical Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 92 from a previous price target of $99 . The Rating was issued on May 10, 2016.Ultragenyx Pharmaceutical Inc is Initiated by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $85. The Rating was issued on Mar 8, 2016.Ultragenyx Pharmaceutical Inc is Initiated by Leerink Partners to Outperform and the brokerage firm has set the Price Target at $80. The Rating was issued on Feb 19, 2016.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).